A cutting-edge probiotic strain
- Complete sequenced and annotated genome
- Thorough characterization and safety profile
- Resistance to gastric acidity and bile
- Survival in human fecal samples after transit
- Strong adhesion to intestinal epithelial
- Support of natural barrier function
L. helveticus LAFTI L10 is a high-quality probiotic strain that can be easily formulated with other ingredients or strains.
Approved health claims in Canada
Natural and Non-prescription Health Products Directorate (NNHPD), the regulatory agency for natural health products in Canada, has approved health claims for L. helveticus LAFTI® L10, such as:
- Promotes gastrointestinal health in physically active adults
- Helps reduce the incidence of cold-like symptoms in adults with exercise-induced stress
A 3-LEVEL CLINICAL RESEARCH PROGRAM IN ACTIVE PEOPLE
Clancy et al 2006 is the first ever clinical study on probiotics for athletes. Lafti L10 helped overtrained athletes to recover an eﬀective immune system similar to healthy athletes by incre
asing IFN-γ levels, a biomarker for natural defenses (p=0.01).
In 2017, LAFTI L10 significantly shortened the duration of URTI-like episodes in elite athletes by 3.4 days (p=0.047) which has been correlated with a significant increase in natural defenses biomarker in blood: CD4/CD8 ratio.
Lafti® L10 significantly reduced the occurrence of symptoms generally associated with cold-like episodes in healthy students (p<0.05). These findings are supported by several animal mechanistic studies.
REDUCTION OF OCCASIONAL GUT DISTURBANCES
Lafti® L10 signifcantly reduces overall occasional gastro-intestinal disturbances (p<0.05) in healthy adults [Welin 2005].
NEW RESULTS ON ANTIOXIDANT STATUS
A recent post-hoc analysis has been published [Michalickova 2018]. This new statistical analysis focused on 22 male participants and looked at both pro-oxidative parameters and anti-oxidative parameters to assess the general oxidative stress. These new results suggest an antioxidant potential of L. helveticus LAFTI® L10 (p<0.05).
Interesting preliminary results on HDL and LDL-cholesterol
Total cholesterol levels, HDL-cholesterol levels, and LDL-cholesterol have been monitored in serum samples. Total cholesterol is significantly lower in LAFTI® L10 group compared to placebo at the end of the study (p<0.05). LAFTI® L10 significantly decreases LDL cholesterol and significantly increases HDL cholesterol compared to baseline (p<0.05). No significant results (final-baseline) observed in the placebo group.